ILIAS Biologics Demonstrates Therapeutic Effect of Anti-Inflammatory Exosomes for Ischemia-Reperfusion-Induced Acute Kidney Injury (AKI)

Anti-inflammatory exosomes could have a place in treating acute kidney injury (AKI) caused by ischemia repercussion injury (IRI), according to a study done by ILIAS Biologics, Inc., in collaboration with Yonsei University of Seoul, South Korea. The ILIAS research team and the Yonsei University research team, led by Professor of Internal Medicine Tae-Hyun Yoo, MD, and Professor of Oral Pathology Jong In Yook, DDS, published the study result online on May 26, 2021 in the official journal of the International Society of Nephrology, Kidney International. ILIAS Biologics, Inc., secured its third proof-of-concept (POC), demonstrating the therapeutic efficacy of their anti-inflammatory exosomes with this successful result in IRI-AKI. This study result comes just after ILIAS Biologics’ second POC in the field of pre-term birth, published in Science Advances in January 2021. With its platform technology EXPLOR® (Exosomes engineering for Protein Loading via Optically Reversible protein-protein interaction), ILIAS has demonstrated the therapeutic applicability of its anti-inflammatory exosomes in multiple inflammation-related therapeutic areas, including sepsis, pre-term birth, and now IRI-AKI.

Login Or Register To Read Full Story